Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

Publication date: Available online 21 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Farhad RavandiInterest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Background: The treatment for pediatric acute myeloid leukemia (AML) has not changed significantly over the past 3 decades, yet outcomes have improved with cure rates increasing from 30% to over 60% of all newly diagnosed children over this period. This improvement in survival has been attributed to both treatment intensification and improved supportive care over the decades, although the precise impact of each remains unknown. Patients and Methods: We retrospectively analyzed a unique cohort of 276 patients with de novo AML diagnosed in childhood, all treated with the same chemotherapy protocol over a 25-year period ...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Original Articles Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Danial A. PollyeaAbstractThere has been little progress in drug development in acute myeloid leukemia (AML) in the recent past. This recently changed with the approval of several therapies for patients with this disease and prompts one to consider which therapies may change practice for patients with AML. To change practice, a therapy must be adopted as a standard of care intervention based on its efficacy and safety profile and must endure as the accepted treatment for a particular indication for a signif...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Jeffrey E. LancetAbstractOlder adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall survival than those who undergo treatment, regardless of treatment type, and improvements in overall survival in the last several decades are largely attributable to the increasing decision to treat rather than offer only supportive care. However, there are a few newer agents that appear promising; these include CPX-351 (a liposoma...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Frederick R. AppelbaumThe persistence of measurable residual disease (MRD) following induction chemotherapy is the single most powerful prognostic factor available to clinicians treating patients with acute myeloid leukemia (AML). How to use this information to guide subsequent therapy is complex, and influenced by the category of AML being treated, the assays used to measure MRD, MRD levels and kinetics, and the spectrum of therapies available to the patient. In this literature-based review, each of these...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Bruno C. MedeirosAbstractDespite advances in treatment for acute myeloid leukemia (AML), the prognosis for patients with relapsed disease is extremely poor. The median overall survival for patients with relapsed AML ranges from 4-6 months and long-term survival from the time of relapse ranges from 5%-20%. Much of the difficulty in establishing a standard of care for relapsed AML is that the disease is clinically and genomically diverse. Nevertheless, significant progress has been made over the past 12 mont...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): John S. WelchTP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy. Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remi...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Cancer CellAuthor(s): Bauke de Boer, Janine Prick, Maurien G. Pruis, Peter Keane, Maria Rosaria Imperato, Jennifer Jaques, Annet Z. Brouwers-Vos, Shanna M. Hogeling, Carolien M. Woolthuis, Marije T. Nijk, Arjan Diepstra, Sebastian Wandinger, Matthias Versele, Ricardo M. Attar, Peter N. Cockerill, Gerwin Huls, Edo Vellenga, André B. Mulder, Constanze Bonifer, Jan Jacob SchuringaSummaryIntra-tumor heterogeneity caused by clonal evolution is a major problem in cancer treatment. To address this problem, we performed label-free quantitative proteomics on primary...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing clones. Here, Marina Konopleva, MD, P... Author: VJHemOnc Added: 09/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hemat... Author: VJHemOnc Added: 09/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Acute Leukemia | Acute Myeloid Leukemia | Drugs & Pharmacology | Leukemia | Marketing | New Drug Applications | Pharmaceuticals